Overview

* PMV Pharma reports Q2 net loss of $21.2 mln, up from $1.2 mln in 2024

* R&D expenses rise to $18.4 mln due to rezatapopt program costs

* Cash reserves of $148.3 mln expected to last until end of 2026

Outlook

* Company expects cash runway to end of 2026

Result Drivers

* R&D EXPENSES - Increase to $18.4 mln driven by rezatapopt program costs

* G&A EXPENSES - Decrease due to reduced stock-based compensation and operational costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.41

Q2 Net -$21.21

Income mln

Q2 $22.88

Operatin mln

g

Expenses

Q2 -$22.88

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for PMV Pharmaceuticals Inc ( PMVP ) is $6.00, about 74.7% above its August 6 closing price of $1.52

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)